|Application ||IHC-P, IF, FC|
|Other Accession||4654, 181768|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Myoblast determination protein 1, Class C basic helix-loop-helix protein 1, bHLHc1, Myogenic factor 3, Myf-3, MYOD1, BHLHC1, MYF3, MYOD|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||MyoD1 (Rhabdomyosarcoma Marker) Antibody - Without BSA is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||BHLHC1, MYF3, MYOD|
|Function||Acts as a transcriptional activator that promotes transcription of muscle-specific target genes and plays a role in muscle differentiation. Together with MYF5 and MYOG, co-occupies muscle-specific gene promoter core region during myogenesis. Induces fibroblasts to differentiate into myoblasts. Interacts with and is inhibited by the twist protein. This interaction probably involves the basic domains of both proteins (By similarity).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a phosphor-protein of 45kDa, identified as MyoD1. This MAb does not cross react with myogenin, Myf5, or Myf6. Antibody to MyoD1 labels the nuclei of myoblasts in developing muscle tissues. MyoD1 is not detected in normal adult tissue, but is highly expressed in the tumor cell nuclei of rhabdomyosarcomas. Occasionally nuclear expression of MyoD1 is seen in ectomesenchymoma and a subset of Wilm s tumors. Weak cytoplasmic staining is observed in several non-muscle tissues, including glandular epithelium and also in rhabdomyosarcomas, neuroblastomas, Ewing s sarcomas and alveolar soft part sarcomas.
Thulasi R et. al. Cell Growth and Differentiation, 1996, 7(4):531-41. | Wesche WA et. al. American Journal of Surgical Pathology, 1995, 19(3):261-9. | Parham DM et. al. Acta Neuropathologica, 1994, 87:605-11. |
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.